Citadel Advisors »

Aligos Therapeutics shares owned by Citadel Advisors

Quarter-by-quarter ownership of Aligos Therapeutics (ALGS) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Aligos Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aligos Therapeutics held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aligos Therapeutics by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $101k 10k 9.80
2025-06-30 $110k 15k 7.21

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Tesla Motors Call Option (TSLA)
NVIDIA Corporation Call Option (NVDA)
Apple Call Option (AAPL)
Meta Platforms Cl A Call Option (META)
Microsoft Corporation Call Option (MSFT)
Spdr Gold Tr Gold Shs Call Option (GLD)
Ishares Tr Russell 2000 Etf (IWM)
Amazon Call Option (AMZN)
Strategy Cl A New Call Option (MSTR)
Alphabet Cap Stk Cl A Call Option (GOOGL)
UnitedHealth Call Option (UNH)
Palantir Technologies Cl A Call Option (PLTR)
Netflix Call Option (NFLX)

View all positions for Citadel Advisors

Top funds holding Aligos Therapeutics

Woodline Partners
Deep Track Capital
Alyeska Investment Group
Sio Capital Management
Readystate Asset Management
Vanguard Group
Adage Capital Partners GP
Baker Bros. Advisors
Hillhouse Capital Advisors
LPL Financial
Renaissance Technologies
Geode Capital Management
Two Sigma Investments
Squarepoint Ops
UBS Group

View all funds holding Aligos Therapeutics